Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Journal of Patient-Reported Outcomes|October 30, 2020
The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trialLærke K Tolstrup, Lars Bastholt, Karin B Dieperink, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2010
Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacySøren Fast, Laszlo Hegedüs, Peter Grupe, et al.
Pigment Cell & Melanoma Research|October 20, 2022
Seasonal variation in effect of anti-PD-1 initiation on overall survival among patients with advanced melanomaEva Ellebaek, Aimilia Schina, Henrik Schmidt, et al.
Acta Oncologica (Stockholm, Sweden)|April 14, 2025
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibilityJonas K Oddershede, Ida K Meklenborg, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2024
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanomaEva Ellebaek, Shawez Khan, Lars Bastholt, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2007
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancerSusanne Larsen, Eva Serup-Hansen, Lisbeth J Andersen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 12, 2005
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanomaAkmal Safwat, Henrik Schmidt, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trialsMarco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, et al.
European Thyroid Journal|October 27, 2017
Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid TissueLars Folkestad, Frans Brandt, Thomas Brix, et al.
Thyroid : Official Journal of the American Thyroid Association|May 30, 2002
Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imagingSteen J Bonnema, Dorthe U Knudsen, Henrik Bertelsen, et al.
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Journal of Patient-Reported Outcomes|October 30, 2020
The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trialLærke K Tolstrup, Lars Bastholt, Karin B Dieperink, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2010
Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacySøren Fast, Laszlo Hegedüs, Peter Grupe, et al.
Pigment Cell & Melanoma Research|October 20, 2022
Seasonal variation in effect of anti-PD-1 initiation on overall survival among patients with advanced melanomaEva Ellebaek, Aimilia Schina, Henrik Schmidt, et al.
Acta Oncologica (Stockholm, Sweden)|April 14, 2025
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibilityJonas K Oddershede, Ida K Meklenborg, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2024
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanomaEva Ellebaek, Shawez Khan, Lars Bastholt, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2007
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancerSusanne Larsen, Eva Serup-Hansen, Lisbeth J Andersen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 12, 2005
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanomaAkmal Safwat, Henrik Schmidt, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trialsMarco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, et al.
European Thyroid Journal|October 27, 2017
Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid TissueLars Folkestad, Frans Brandt, Thomas Brix, et al.
Thyroid : Official Journal of the American Thyroid Association|May 30, 2002
Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imagingSteen J Bonnema, Dorthe U Knudsen, Henrik Bertelsen, et al.
Pageof 14